case_images: PMC10907001_01
case_images: Timeline of events in our patient.
case_images: cro-2024-0017-0001-536552_F01.jpg
case_images: PMC10907001_01_cro-2024-0017-0001-536552_F01.jpg
case_images: F1
case_images: Figure 1 represents the timeline of events in this patient.
case_images: Serial imaging and tumor marker (CA19-9) while on gemcitabine/erlotinib. a CA19-9 level declined on gemcitabine/erlotinib (indicating response), with a fast rise after discontinuation of this treatment (indicating disease progression). b The white arrow points to a represented right upper lobe pulmonary nodule (area of metastasis of pancreatic cancer to the lung). The represented nodule was stable while on gemcitabine/erlotinib (size is measured by the radiologist on the same axis in all images and is indicated in each image). The CT scan taken on 07/13 represents the emergence of pneumonitis (representative area marked by red lining) at which time gemcitabine/erlotinib was discontinued. CT scan on 08/25 shows resolution of pneumonitis with steroid treatment but an increase in the size of the represented nodule (indicating tumor growth). Innumerable other sub-centimeter nodules in bilateral lungs progressed within the same timeline after discontinuation of gemcitabine/erlotinib (not shown here).
case_images: cro-2024-0017-0001-536552_F02.jpg
case_images: PMC10907001_01_cro-2024-0017-0001-536552_F02.jpg
case_images: F2
case_images: Fortunately, this was followed by stabilization of the tumor size on imaging and declining CA19-9 (Fig. 2). This was followed by the progression of the tumor based on both imaging and serial CA19-9 levels (Fig. 2).